Clinical Trials

Find a Trial

Trial Summary

Protocol No.PHO-COG-FALLON-ACNS0332
StatusOPEN TO ACCRUAL
Principal InvestigatorPradhan, Kamnesh
ScopeNational
PhasePhase III
Age GroupChildren
TitleEfficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Subjects
DescriptionThis randomized phase III trial is studying different chemotherapy and radiation therapy regimens to compare how well they work in treating young patients with newly diagnosed, previously untreated, high-risk medulloblastoma or supratentorial primitive neuroectodermal tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Isotretinoin may help chemotherapy work better by making tumor cells more sensitive to the drugs. Radiation therapy uses high-energy x-rays to kill tumor cells. Carboplatin may make tumor cells more sensitive to radiation therapy. It is not yet known which chemotherapy and radiation therapy regimen is more effective in treating brain tumors.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • Be between 3 and 21 years of age
  • Have a histologically confirmed diagnosis of medulloblastoma or supratentorial primitive neuroectodermal tumor (PNET)
  • Have undergone stereotactic biopsy or attempted neurosurgical resection of the tumor within the past 31 days
For a full list of participation criteria, please visit clinicaltrials.gov.
Applicable Disease SitesBrain Tumors (Child)
Participating InstitutionsIndiana University (IU)
  • Indiana University Hospital / IU Simon Cancer Center
  • Riley Hospital for Children
Treatment TypeTreatment
ContactMelissa Lee, Phone: +1 317-944-4281
Pager: 312-1228
Email: mellee@iu.edu